US generics player ANI Pharmaceuticals is looking to buy manufacturing assets to support its expansion from the solid and liquid oral-dose sector into the injectables arena. Having recently acquired four development-stage generic injectables from Coeptis Pharmaceuticals, the Minnesota-based firm currently has a pipeline of six injectable drugs.
“With the money we have available to us as we move into the injectable platform, we will be looking for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?